Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Up 76.9% in March

Virios Therapeutics, Inc. (NASDAQ:VIRI) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 170,200 shares, an increase of 76.9% from the February 29th total of 96,200 shares. Based on an average daily volume of 370,900 shares, the days-to-cover ratio is presently 0.5 days.

Virios Therapeutics Stock Performance

VIRI opened at $0.48 on Thursday. Virios Therapeutics has a one year low of $0.28 and a one year high of $2.42. The company has a market cap of $9.32 million, a price-to-earnings ratio of -1.73 and a beta of 1.82. The business’s fifty day moving average is $0.40 and its two-hundred day moving average is $0.61.

Virios Therapeutics (NASDAQ:VIRI) last released its earnings results on Thursday, February 29th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03. On average, analysts predict that Virios Therapeutics will post -0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Virios Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its stake in Virios Therapeutics by 576.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 109,196 shares of the company’s stock worth $26,000 after acquiring an additional 93,050 shares during the last quarter. State Street Corp acquired a new stake in Virios Therapeutics during the second quarter worth about $45,000. Citadel Advisors LLC acquired a new stake in Virios Therapeutics during the second quarter worth about $46,000. Renaissance Technologies LLC boosted its position in shares of Virios Therapeutics by 33.3% in the fourth quarter. Renaissance Technologies LLC now owns 235,400 shares of the company’s stock worth $56,000 after buying an additional 58,800 shares during the period. Finally, Susquehanna International Group LLP boosted its position in shares of Virios Therapeutics by 343.3% in the first quarter. Susquehanna International Group LLP now owns 161,811 shares of the company’s stock worth $59,000 after buying an additional 125,311 shares during the period. 9.05% of the stock is currently owned by institutional investors and hedge funds.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.